Thesis

LIST OF FIGURES

Figure No.	Title	Page No.
Figure 1.1	Cartoon conformation of AFP	**2**
Figure 1.2	Structure of chitin (N-acetyl-glucosamine)	**4**
Figure 1.3	Proportion of emerging infectious diseases caused by different taxonomic groups of pathogens	**6**
Figure 1.4	Targets of systemic antifungal agents	**11**
Figure 1.5	Sites of action and mechanisms of systemic antifungal agents. Glucan synthase complex are the putative target binding site of echinocandins	**13**
Figure 4.1	Effect of soluble starch and CSL with proteose peptone under varying concentration on mycelial growth and afp production in batch culture under submerged fermentation by *A. giganteus* MTCC 8408	**60**
Figure 4.2	Effect of initial pH and temperature on mycelial growth and afp production in modified Olson media under submerged fermentation by *A. giganteus* MTCC 8408	**61**
Figure 4.3	Impact of selected factor at their assigned ratio $Y_{p/x}$ by A. giganteus MTCC: 8408 in submerged fermentation	**64**
Figure 4.4	Morphological differentiation of *Aspergillus giganteus* MTCC 8408 cell on nutrient dynamics and optimization. Lateral resolution: 2–10 lm; magnification: 5KX; EHT: 18.00 kV; WD: 9.5 mm	**66**
Figure 4.5	Severity index interaction plot and performance distribution plot	**69**

Figure 4.6	Morphological behaviors of *Aspergillus giganteus* MTCC 8408, showing the effect of various nutrients composition on optimization. Lateral resolution: 2–10 mm; magnification: 5KX; EHT: 18.00 KV; WD: 9.5 mm.	**72**
Figure 4.7	Relative influence of factors and interactions.	**74**
Figure 4.8	Performance distribution plot: current vs. improved condition.	**76**
Figure 4.9	A typical time course of carbohydrates consumption, viz., (a) soluble starch, (b) glucose, (c) maltose, (d) sucrose and (e) lactose vs. mycelial biomass and antifungal protein production in submerged fermentation under statistically optimized new modified culture conditions (using Taguchi DOE L_{27} OA).	**78-80**
Figure 4.10	Fitting experimental data and calculated RMSE value with various model, viz., Monod, Moser, Tessier, Blackman, Haldane and Logistic model.	**82-84**
Figure 4.11	Fitting experimental data and calculated RMSE value in macroscopic model (Logistic) linking with microscopic model (symmetric branching) in exponential growth phase.	**87**
Figure 4.12	Simulation profile of predicted kinetic model with μ_m (max. specific growth rate), K_s (substrate saturation constant), E (mean hyphal extension rate) and S (substrate concentration).	**89-90**
Figure 4.13	Purification of the antifungal protein from the intracellular extract of *Aspergillus giganteus* MTCC 8408, (a) CMC cation exchange chromatography of the crude extract (50-70%), (b) Sephadex-100 gel filtration chromatography of fraction F-4.	**91-92**
Figure 4.14	Disc diffusion study of crude afp and Acp-N84.	**94**
Figure 4.15	Dose response study of Acp-N84.	**95**

Figure 4.16	Imaging *in vitro* antibiofilm activity: Appearance of different cell morphologies of *C. albicans* using confocal microscopy	**96**
Figure 4.17	Imaging *in vitro* antibiofilm activity: Atomic force micrographs	**97**
Figure 4.18	Imaging *in vitro* antibiofilm activity: Scanning electron micrograph of the 48 h biofilm formed in *C. albicans*	**97**
Figure 4.19	Time killing assay of *Candida albicans*, protein Acp-N84 was investigated *in vitro* with conventional antifungal agents	**98**
Figure 4.20	Cytotoxicity assay in human cervical cancer (HeLa) cells on treatment with peptides	**100**
Figure 4.21	Apoptotic detection by Hoechst 33342/Propidium iodide staining in HeLa cells.	**101**
Figure 4.22	SDS–polyacrylamide gel electrophoresis, molecular mass and ESI-MS spectrum of purified Acp-N84 protein.	**102**
Figure 4.23	FTIR spectrum of purified Acp-N84 protein.	**104**
Figure 4.24	Peptide mass fingerprinting of Acp-N84 by MALDI-TOF MS.	**105**
Figure 4.25	Prediction of disulfide bridges formation (DISULFIND)	**108**
Figure 4.26	Cleavage site prediction of the signal sequence Acp-N84 (SignalP1-4.1)	**108**
Figure 4.27	Protein structure prediction (PSIPRED)	**110**